Brawn Biotech Limited (BOM:530207)
21.05
-1.05 (-4.75%)
At close: Nov 6, 2026
Brawn Biotech Revenue
Brawn Biotech had revenue of 57.66M INR in the quarter ending September 30, 2026, with 17.88% growth. This brings the company's total for the last twelve months to 180.90M, up 7.66% year-over-year. In the fiscal year ending March 31, 2026, Brawn Biotech had annual revenue of 169.78M with 26.09% growth. That makes Brawn Biotech the 42,480th largest company in the world by revenue and 4,339th in India.
Revenue (ttm)
180.90M
Revenue Growth
+7.66%
P/S Ratio
0.35
Revenue / Employee
30.15M
Employees
6
Market Cap
63.16M
Revenue by Geography
- India 145.32M 85.6%
- Unallocated 24.46M 14.4%
Fiscal year ended Mar 31, 2026 See the full Brawn Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 169.78M | 35.13M | 26.09% |
| Mar 31, 2025 | 134.65M | -30.30M | -18.37% |
| Mar 31, 2024 | 164.95M | -57.42M | -25.82% |
| Mar 31, 2023 | 222.36M | 136.15M | 157.93% |
| Mar 31, 2022 | 86.21M | -263.55M | -75.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 1.17B |
| Beryl Drugs | 213.23M |
| Fabino Enterprises | 208.42M |
| Unjha Formulations | 152.79M |
| Decipher Labs | 138.51M |
| Norris Medicines | 76.00M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Ganga Pharmaceuticals | 28.21M |